Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915. Halda’s oral RIPTACs use a “hold‑and‑kill” mechanism designed to overcome common resistance pathways in solid tumors, positioning J&J to expand its oncology portfolio. Halda reported encouraging Phase 1/2 activity in metastatic castrate‑resistant prostate cancer, including PSA reductions and RECIST responses across dose cohorts. J&J said it will accelerate the ongoing study and integrate Halda’s technology with its existing prostate cancer assets. The deal bundles a novel degrader‑adjacent modality with a clinical program that showed tolerable safety and early signs of efficacy, giving J&J a development asset and a platform bet aimed at resistance‑prone cancers.